Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity o f Ascending Doses of PT0I (Pegtomarginase) in Subjects With Advanced Malignancies

NCT04136834 is registered in ClinicalTrials.gov with Athenex, Inc. as lead sponsor.

NCT NCT04136834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04136834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity o f Ascending Doses of PT0I (Pegtomarginase) in Subjects With Advanced Malignancies
Lead sponsor
Athenex, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
April 21, 2021
Completion date
December 1, 2022
Enrollment
62 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies